Pulmonx (NASDAQ:LUNG) & EUDA Health (NASDAQ:EUDA) Head to Head Contrast

EUDA Health (NASDAQ:EUDA) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Earnings & Valuation

This table compares EUDA Health and Pulmonx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EUDA Health	$4.01 million	19.55	-$15.36 million	($0.12)	-17.58
Pulmonx	$83.79 million	0.93	-$56.39 million	($1.43)	-1.34

EUDA Health has higher earnings, but lower revenue than Pulmonx. EUDA Health is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares EUDA Health and Pulmonx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EUDA Health	N/A	N/A	N/A
Pulmonx	-62.88%	-69.76%	-36.26%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for EUDA Health and Pulmonx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EUDA Health	1	0	0	1	2.50
Pulmonx	1	4	5	0	2.40

Pulmonx has a consensus price target of $6.81, suggesting a potential upside of 254.54%. Given Pulmonx’s higher possible upside, analysts clearly believe Pulmonx is more favorable than EUDA Health.

Institutional & Insider Ownership

4.4% of EUDA Health shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 6.8% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

EUDA Health has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.

Summary

EUDA Health beats Pulmonx on 8 of the 15 factors compared between the two stocks.

About EUDA Health

EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.